Sofinnova Partners Invests in LimFlow
PARIS – Dechert LLP advised Sofinnova Partners in the Series C financing of LimFlow, a developer of innovative, peripheral endovascular technology transforming the treatment of critical limb ischemia (CLI), for €27 million.
Sofinnova Partners led the financing round with continued participation from existing round B investors Bpifrance and Balestier, and will join the company’s board of directors. The investment is the first for the newly raised Sofinnova Crossover I Fund.
Proceeds from the Series C financing will fund LimFlow's major strategic initiatives through the second half of 2020.
The Paris-based team advising Sofinnova Partners was led by Anne-Charlotte Rivière with assistance from Anne-Sophie Gallot.
About Dechert
Dechert is a global law firm focused on sectors with the greatest complexities and highest regulatory demands. We deliver practical commercial insight and judgment to our clients' most important matters. Nothing stands in the way of giving clients the best of the firm's entrepreneurial energy and seamless collaboration in a way that is distinctively Dechert.
Read the press release in French (PDF): Dechert a conseillé Sofinnova Partners dans le cadre de son investissement dans Limflow
